An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3

A J Bett, W Haddara, L Prevec, F L Graham, A J Bett, W Haddara, L Prevec, F L Graham

Abstract

Human adenoviruses (Ads) are attracting considerable attention because of their potential utility for gene transfer and gene therapy, for development of live viral vectored vaccines, and for protein expression in mammalian cells. Engineering Ad vectors for these applications requires a variety of reagents in the form of Ads and bacterial plasmids containing viral DNA sequences and requires different strategies for construction of vectors for different purposes. To simplify Ad vector construction and develop a procedure with maximum flexibility, efficiency, and cloning capacity, we have developed a vector system based on use of Ad5 DNA sequences cloned in bacterial plasmids. Expanded deletions in early region 1 (3180 bp) and early region 3 (2690 or 3132 bp) can be combined in a single vector that should have a capacity for inserts of up to 8.3 kb, enough to accommodate the majority of cDNAs encoding proteins with regulatory elements. Genes can be inserted into either early region 1 or 3 or both and mutations or deletions can be readily introduced elsewhere in the viral genome. To illustrate the flexibility of the system, we have introduced a wild-type early region 3 into the vectors, and to illustrate the high capacity for inserts, we have isolated a vector with two genes totaling 7.8 kb.

References

    1. Virology. 1973 Apr;52(2):456-67
    1. J Virol. 1976 Aug;19(2):685-708
    1. J Gen Virol. 1977 Jul;36(1):59-74
    1. Cell. 1977 Sep;12(1):243-9
    1. Cell. 1979 Jul;17(3):683-9
    1. Nucleic Acids Res. 1979 Nov 24;7(6):1513-23
    1. Cell. 1980 Jul;20(3):787-95
    1. Nature. 1981 Jul 23;292(5821):380-2
    1. Gene. 1982 Jul-Aug;19(1):33-42
    1. Nature. 1983 Jan 13;301(5896):172-4
    1. Cell. 1983 Jul;33(3):695-703
    1. Nucleic Acids Res. 1983 Sep 10;11(17):6003-20
    1. Nature. 1983 Sep 29-Oct 5;305(5933):448-51
    1. Virology. 1984 Jun;135(2):503-14
    1. Virology. 1985 Jan 15;140(1):28-43
    1. EMBO J. 1984 Dec 1;3(12):2917-22
    1. J Virol. 1986 Jan;57(1):267-74
    1. Cell. 1986 Apr 25;45(2):229-36
    1. Gene. 1986;50(1-3):161-71
    1. J Virol. 1987 Aug;61(8):2555-8
    1. EMBO J. 1987 Jun;6(6):1733-9
    1. Virology. 1988 Apr;163(2):614-7
    1. Virology. 1988 May;164(1):1-14
    1. Nucleic Acids Res. 1988 Jul 11;16(13):6127-45
    1. Gene. 1989 Oct 30;82(2):201-8
    1. J Virol. 1990 May;64(5):2047-56
    1. J Virol. 1991 Feb;65(2):598-605
    1. Virology. 1991 Jun;182(2):578-96
    1. J Virol. 1992 Feb;66(2):723-31
    1. Curr Top Microbiol Immunol. 1992;158:39-66
    1. Virus Res. 1993 Apr;28(1):67-90
    1. J Virol. 1993 Oct;67(10):5911-21
    1. J Clin Invest. 1993 Sep;92(3):1580-6

Source: PubMed

3
購読する